Vaginal candidiasis prevalence, associated factors, and antifungal susceptibility patterns among pregnant women attending antenatal care at bule hora university teaching hospital, Southern Ethiopia
- PMID: 39350045
- PMCID: PMC11441096
- DOI: 10.1186/s12884-024-06844-x
Vaginal candidiasis prevalence, associated factors, and antifungal susceptibility patterns among pregnant women attending antenatal care at bule hora university teaching hospital, Southern Ethiopia
Abstract
Background: Vulvovaginitis is common in women of reproductive age group characterized by purulent white discharge. The incidence of vulvovaginitis has risen recently due to the resistance of Candida species to commonly used antifungal agents and recurrent infections.
Objective: The study aimed to determine the prevalence, associated factors, and antifungal susceptibility patterns of vaginal candidiasis among pregnant women attending Bule Hora University Teaching Hospital.
Methods: A hospital-based cross-sectional study was conducted from May 2023 to August 2023. Using systematic random sampling, 317 pregnant women participated in the study. Sabouraud Dextrose Agar and Chromogenic Candida Differential Agar were used to isolate and identify Candida species from clinical samples. Antifungal susceptibility was performed using a modified disc diffusion method. Epi data version 4.6 was used for data entry and Statistical Packages for Social Sciences version 25 was used for statistical analysis. A P-value < 0.05 was declared statistically significant.
Result: The prevalence of vaginal candidiasis was 26.8% (95%, CI 21.9-31.72%). History of using contraceptives (AOR = 5.03, 95%CI, 1.21-11.37), past vaginal candidiasis (AOR = 6, 95%CI, 1.61-12.92), pregnant women infected with human immunodeficiency virus (HIV) (AOR = 4.24, 95%CI, 1.23-14.14), diabetic mellitus (AOR = 2.17, 95%CI, 1.02-4.64), history of antibiotic use (AOR = 3.55, 95%CI, 1.67-12.75), pregnant women in third trimester (AOR = 8.72, 95%CI, 1.30-23.07), were the significantly associated factors for vaginal candidiasis. The study revealed that itraconazole, amphotericin B, and miconazole were the most effective antifungal drugs for all Candida isolates.
Conclusion: The present study has identified a high prevalence of vaginal candidiasis among pregnant women. The isolated Candida species showed resistance to fluconazole, ketoconazole, and clotrimazole. Therefore, healthcare providers should increase awareness of the risks of Candida infections to reduce Candida species among pregnant women. Physicians should prescribe suitable medications based on antifungal drug test outcomes to treat pregnant women with vaginal candidiasis.
Keywords: Antenatal care; Bule hora; Pregnant women; Vaginal candidiasis.
© 2024. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Figures
Similar articles
-
Antifungal susceptibility profiles of Candida and non-albicans species isolated from pregnant women: implications for emerging antimicrobial resistance in maternal health.Microbiol Spectr. 2025 Jul;13(7):e0078725. doi: 10.1128/spectrum.00787-25. Epub 2025 Jun 2. Microbiol Spectr. 2025. PMID: 40454865 Free PMC article.
-
Symptomatic vulvovaginal candidiasis and antifungal resistance in HIV-1 positive women at Mbarara city health centre IV.Sci Rep. 2025 Jul 6;15(1):24123. doi: 10.1038/s41598-025-09215-4. Sci Rep. 2025. PMID: 40619549 Free PMC article.
-
Prevalence, risk factors and antifungal susceptibility pattern of Candida species among pregnant women at Debre Markos Referral Hospital, Northwest Ethiopia.BMC Pregnancy Childbirth. 2019 Dec 30;19(1):527. doi: 10.1186/s12884-019-2494-1. BMC Pregnancy Childbirth. 2019. PMID: 31888537 Free PMC article.
-
Prevalence, antifungal susceptibility and etiology of vulvovaginal candidiasis in sub-Saharan Africa: a systematic review with meta-analysis and meta-regression.Med Mycol. 2022 Jul 9;60(7):myac037. doi: 10.1093/mmy/myac037. Med Mycol. 2022. PMID: 35781514
-
Drug-resistant oral candidiasis in patients with HIV infection: a systematic review and meta-analysis.BMC Infect Dis. 2024 May 31;24(1):546. doi: 10.1186/s12879-024-09442-6. BMC Infect Dis. 2024. PMID: 38822256 Free PMC article.
Cited by
-
Knowledge and usage patterns of clotrimazole vaginal cream and tablet amongst females: a cross-sectional study.Front Pharmacol. 2025 Aug 8;16:1484238. doi: 10.3389/fphar.2025.1484238. eCollection 2025. Front Pharmacol. 2025. PMID: 40860867 Free PMC article.
-
Antifungal susceptibility profiles of Candida and non-albicans species isolated from pregnant women: implications for emerging antimicrobial resistance in maternal health.Microbiol Spectr. 2025 Jul;13(7):e0078725. doi: 10.1128/spectrum.00787-25. Epub 2025 Jun 2. Microbiol Spectr. 2025. PMID: 40454865 Free PMC article.
-
Development and characterization of fenticonazole nitrate-loaded cubogel for the management of vaginal candidiasis.Int J Pharm X. 2025 Jul 10;10:100355. doi: 10.1016/j.ijpx.2025.100355. eCollection 2025 Dec. Int J Pharm X. 2025. PMID: 40703664 Free PMC article.
References
-
- Mohamed AO, Mohamed MS, Mallhi TH, Hussain MA, Jalloh MA, Omar KA, et al. Prevalence of vulvovaginal candidiasis among pregnant women in Africa: a systematic review and meta-analysis. J Infect Developing Ctries. 2022;16(08):1243–51. - PubMed
-
- Gonçalves B, Ferreira C, Alves CT, Henriques M, Azeredo J, Silva S. Vulvovaginal candidiasis: Epidemiology, microbiology and risk factors. Crit Rev Microbiol. 2016;42(6):905–27. - PubMed
-
- Denning DW, Kneale M, Sobel JD, Rautemaa-Richardson R. Global burden of recurrent vulvovaginal candidiasis: a systematic review. Lancet Infect Dis. 2018;18(11):e339–47. - PubMed
-
- Mendling W, Friese K, Mylonas I, Weissenbacher E-R, Brasch J, Schaller M, et al. Vulvovaginal candidosis (excluding chronic mucocutaneous candidosis). Guideline of the German Society of Gynecology and Obstetrics (AWMF registry 015/072, S2k level, December 2013). Geburtshilfe Frauenheilkd. 2015;75(04):342–54. - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous